VIIV HEALTHCARE PTY LTD

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Assess Relative Bioavailability and Food Effect of New Formulations of GSK2248761

Phase 1

Completed

Conditions: HIV Infections
Infection, Human Immunodeficiency Virus

Interventions: Drug: GSK2248761 formulation 1
Drug: GSK2248761 formulation 2 or 4
Drug: GSK2248761 reference formulation
Drug: GSK2248761 formulation 3

First Posted Date: 2009-12-14

Last Posted Date: 2020-03-27

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 24

Registration Number: NCT01031472

Locations: 🇺🇸
GSK Investigational Site, Buffalo, New York, United States

Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: BMS-663068
Drug: Ritonavir

First Posted Date: 2009-11-09

Last Posted Date: 2020-01-03

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 50

Registration Number: NCT01009814

Locations: 🇩🇪
GSK Investigational Site, Berlin, Germany

A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India

Conditions: Human Immunodeficiency Virus (HIV)

First Posted Date: 2009-10-09

Last Posted Date: 2018-09-27

Lead Sponsor: ViiV Healthcare

Registration Number: NCT00992654

A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects

Phase 2

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: GSK1349572
Drug: efavirenz

First Posted Date: 2009-08-03

Last Posted Date: 2018-01-16

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 208

Registration Number: NCT00951015

Locations: 🇪🇸
GSK Investigational Site, Madrid, Spain

A Pilot Study Assessing the Integrase Inhibitor GSK1349572 in HIV-infected Persons With Virus Resistant to Raltegravir

Phase 2

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: GSK1349572 (Cohort I)
Drug: GSK1349572 (Cohort II)

First Posted Date: 2009-08-03

Last Posted Date: 2015-12-04

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 51

Registration Number: NCT00950859

Locations: 🇪🇸
GSK Investigational Site, Sevilla, Spain

Safety and Tolerability Study to Evaluate Lower Dose of GSK2248761 in Antiretroviral Treatment-Naive HIV-1 Infected Adults.

Phase 2

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: GSK2248761
Drug: Lopinavir/ritonavir
Drug: HAART
Drug: Placebo

First Posted Date: 2009-07-24

Last Posted Date: 2018-11-29

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 8

Registration Number: NCT00945282

Locations: 🇦🇷
GSK Investigational Site, Buenos Aires, Argentina

Study to Compare the Safety and Anti-HIV Effect of GSK1265744 Versus Placebo in HIV-1 Infected Adults (ITZ112929)

Phase 2

Completed

Conditions: Infection, Human Immunodeficiency Virus

Interventions: Drug: Placebo
Drug: GSK1265744 5mg
Drug: GSK1265744 30mg

First Posted Date: 2009-06-15

Last Posted Date: 2017-12-06

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 9

Registration Number: NCT00920426

Locations: 🇺🇸
GSK Investigational Site, Charlotte, North Carolina, United States

GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/Ritonavir

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Darunavir
Drug: Lopinavir/ritonavir
Drug: Etravirine
Drug: GSK1349572
Drug: Ritonavir

First Posted Date: 2009-03-23

Last Posted Date: 2012-02-22

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 17

Registration Number: NCT00867152

Locations: 🇺🇸
GSK Investigational Site, Buffalo, New York, United States

Safety And Efficacy Of Maraviroc In Patients For HIV Patients (Regulatory Post Marketing Commitment Plan)

Completed

Conditions: CCR5-tropic HIV-1 Infection

Interventions: Drug: CELSENTRI® Tablets

First Posted Date: 2009-03-18

Last Posted Date: 2020-01-02

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 68

Registration Number: NCT00864474

Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc

Phase 4

Completed

Conditions: AIDS

Interventions: Drug: Maraviroc
Drug: Placebo
Drug: Vardenafil

First Posted Date: 2009-03-02

Last Posted Date: 2013-01-25

Lead Sponsor: ViiV Healthcare

Target Recruit Count: 18

Registration Number: NCT00853840

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy